Seasonal influenza vaccination good value for money for most risk groups in South Africa
- PDF / 170,109 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 39 Downloads / 190 Views
1
Seasonal influenza vaccination good value for money for most risk groups in South Africa South Africa’s seasonal influenza vaccination strategy of targeting high-risk populations during routine visits is cost effective, according to a study published in Vaccine. The study used the WHO Cost-Effectiveness Tool for Seasonal Influenza Vaccination (CETSIV) to assess the costs and benefits of the seasonal influenza vaccination programme using trivalent inactivated influenza vaccine (TIV) given during visits to health facilities for routine care, compared with no vaccination, for different risk groups in South Africa. The 2018 influenza vaccination campaign was modelled for each risk group from both a public healthcare provider and a societal perspective. The model was populated with country-specific data on the burden of influenza disease, vaccine efficacy, QALY loss, vaccination programme cost, cost of influenza-associated illness and cost of the management of vaccine-related adverse events. The model showed that the highest clinical benefits of the vaccination programme in terms of the number of influenza-associated clinical events averted at 2018 coverage levels were observed in persons living with HIV/AIDS (PLWHA) and in persons with other underlying medical conditions (2.40% and 1.82% reduction, respectively). The vaccination programme was cost effective, compared with no vaccination, for all risk groups at a cost-effectiveness threshold of $US3400 per disability-adjusted life-year (DALY) averted, except for children aged 6–59 months. The incremental cost-effectiveness ratios (ICERs) ranged from $1749 for PLWHA to $2618 per QALY gained (year 2018 values) for persons with other underlying medical conditions from a public healthcare provider perspective. From a societal perspective, the vaccination programme was cost saving for PLWHA, persons with other underlying medical conditions and pregnant women, and cost effective for persons aged ≥ 65 years (ICER $2034/QALY). Edoka I, et al. A cost-effectiveness analysis of South Africa’s seasonal influenza vaccination programme. Vaccine : 30 Nov 2020. Available from: URL: http:// doi.org/10.1016/j.vaccine.2020.11.028
1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803521592
PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868
Data Loading...
